Cyprotex launches genomic service
gADME will enable drug developers to understand effect of genetic polymorphisms
Cyprotex, a provider of ADME-Tox services, has added a new Genomic ADME service to its portfolio, which provides researchers with data about genomic differences in drug response in early stage drug development.
The new service, called gADME, enables drug developers to identify which enzymes play a role in the metabolism of their drugs, to understand the impact of genetic polymorphisms on that metabolism, and to devise dose adjustment strategies.
The Macclesfield, Cheshire-based firm says drug developers will be able to improve patient care through identifying and compensating for variability in patient drug response, and enable personalised dose regimens to be set up.
Katya Tsaioun, Cyprotex’s chief scientific officer, says the gADME service will enable drug developers to understand the effect of genetic polymorphisms on drug toxicity and efficacy.
‘This understanding will enable drug developers to identify appropriate dose adjustment strategies personalised for an individual’s genotype. This in turn can enable existing therapies to be repositioned, and successful development of drugs that would have heretofore been discarded,’ she said.
Cyprotex’s gADME service combines genomics with ADME to predict inter-individual variability in human pharmacokinetics. The technology uses a panel of proprietary enzyme systems providing a range of drug metabolising enzymes, including genetic variants of these enzymes.